Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 10/20 | 0.65 |
| ▸ | VIPR1 | P32241 | 9/20 | 0.65 |
| ▸ | TFPI | P10646 | 1/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | HRAS | P01112 | 1/20 | 0.54 |
| ▸ | KRAS | P01116 | 1/20 | 0.54 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.54 |
| ▸ | CCKBR | P32239 | 1/20 | 0.54 |
| ▸ | GLP1R | P43220 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29694509 | 0.96 | VIPR2 (0.66) | VIPR2VIPR1TFPI | |
| SCHEMBL29694508 | 0.96 | VIPR2 (0.66) | VIPR2VIPR1TFPIGLP1R | |
| SCHEMBL29694510 | 0.92 | VIPR2 (0.61) | VIPR2VIPR1TFPI | |
| SCHEMBL30432804 | 0.92 | VIPR1 (0.70) | VIPR2VIPR1TFPIGLP1R | |
| SCHEMBL30176424 | 0.91 | VIPR1 (0.63) | VIPR2VIPR1TFPIGLP1R | |
| SCHEMBL30478240 | 0.90 | VIPR2 (0.62) | VIPR2VIPR1KEAP1 | |
| SCHEMBL30176435 | 0.90 | VIPR1 (0.69) | VIPR2VIPR1TFPICCKBRGLP1R | |
| SCHEMBL30929948 | 0.90 | VIPR2 (0.70) | VIPR2VIPR1TFPIKEAP1GLP1R | |
| SCHEMBL30929981 | 0.90 | VIPR2 (0.70) | VIPR2VIPR1TFPIKEAP1GLP1R | |
| SCHEMBL30567776 | 0.89 | TFPI (0.69) | VIPR2VIPR1TFPIGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629409-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2026-05-19 | — | — | US | disclosed |
| US-20240226261-A9 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-07-11 | — | — | US | disclosed |
| US-20240131136-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-04-25 | — | — | US | disclosed |
| US-11844828-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-12-19 | — | — | US | disclosed |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-08-10 | — | — | US | disclosed |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-03-02 | — | — | US | disclosed |
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-09-15 | — | — | US | disclosed |
| US-20220152182-A1 | VACCINE | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-05-19 | — | — | US | disclosed |
| US-11266731-B2 | Vaccine | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288190-A1 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | VIPR2 860/4885VIPR1 814/4885TFPI 1391/4885 |
| US-20230248816-A9 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE | CFD, PEPD, SERPINA6 | VIPR2 860/4885VIPR1 814/4885TFPI 1391/4885 |
| US-12629409-B2 | Vaccine | MRPL21, STT3B, CD47 | VIPR2 3765/4885VIPR1 3836/4885TFPI 2332/4885 |
| US-20230066762-A1 | IMMUNOGENIC COMPOSITION | CXCL10, CCL2, CCL11 | VIPR2 1911/4885VIPR1 1718/4885TFPI 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.